Rocafiguera, A. O., Hus, M., Gazitua, R., Liao, A., Janowski, W., Lee, C., Mikala, G., Jurczyszyn, A., Berkovits, A., Lu, J., Schjesvold, F., Ling, S., Spencer, A., Ailawadhi, S., Buck, T. T., Khan, U., Suzan, F., Stefanova-Urena, M., Hungria, V., Špička, I. (2026). Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7516